Simultaneous Estimation of Genotoxic Impurities 4-Nitrobenzene Trifluoride, 4-Aminobenzene Trifluoride, and Benzo Trichloride in Cinacalcet Hydrochloride by GC-MS/MS Method
DOI:
https://doi.org/10.37285/ijpsn.2021.14.6.6Abstract
The main objective of this study is to develop and validate a novel, fast, and more sensitive gas chromatography-mass spectrometry (GC-MS/MS) method for the simultaneous estimation of 4-Nitrobenzotrifluoride (4-NBTF), 4-Amino-benzotrifluoride (4-ABTF), and Benzotrichloride (BTC) impurities in Cinacalcet hydrochloride (CH). The chromate-graphic separations were performed on a DB-624, 30m × 0.32mm × 1.8µm column with injector temperature of 150°C, and mode of injection is split with asplit ratio 1: 20. The carrier gas used was helium with a flowrate 1.5 mL/min, and theinjection load was 1.0 µL. Mass spectrometry quantitation was achieved by aquadrupole analyser with EI (Electron Ionization) ion source atasource temperature of 250ºC and interface temperature of 250ºC. The retention times for 4-NBTF, 4-ABTF, and BTC were at 6.13, 6.74and 7.64min, respectively. The calibration curve was linear over the concentration ranging from LOQ level to 150 % level with the correlation coefficient (r) of > 0.99. The percentage recovery was found to be within the specified range, i.e., 70.0 to 130.0 for the three impurities. The limit of detection (LOD) was established to 0.19, 0.19, and 0.18 ppm, whereas thelimit of quantification (LOQ) was obtained to 1.14, 1.12, and 1.11 ppm for 4-NBTF, 4-ABTF, and BTC, respectively. The test solutions with impurities were found to be stable in the diluent for 24 hours. A simple GC-MS/MS method was developed and validated for simultaneous estimation of three impurities in CH. The method was accurate, precise, linear, specific, sensitive, robust, and rugged as per ICH guidelines. The method has been applied to the real-time batch analysis and found to be suitable for routine quality control analysis of CH.
Downloads
Metrics
Keywords:
Cinacalcet hydrochloride, 4-Nitrobenzotrifluoride, 4-Aminobenzotrifluoride, Benzotrichloride, Genotoxic impurities, ICH guidelines, GC-MS/MS, SIM, AutoSRM, EI
Downloads
Published
How to Cite
Issue
Section
References
Ahirrao VK, Jadhav RA, Rane VP, Bhamare HR and Yeole RD (2020). Time-dependent selected reaction monitoring-based GC-MS/MS method for estimation of genotoxic impurities in new antibacterial agent: alalevonadifloxacin mesylate vinod. J Anal Sci Technol 11(1): 11-22. DOI:10.1186/s40543-020-00214-w.
Ashby J, and Tennant RW (1988). Chemical structure, salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the US NCI/NTP. Mutat Res 204: 17-115.DOI: 10.1016/0165-1218(88)90114-0.
Bhushan R and Dubey R (2011). Indirect reversed-phase high-performance liquid chromatographic and direct thin-layer chromatographic enantioresolution of (R,S)-Cinacalcet. Biomed Chromatogr 25: 674-679. DOI:10.1002/bmc.1502.
Bouder F (2008). Regulating impurities in pharmaceutical products: a tolerability of riskapproach?. Expert Rev Clin Pharmacol 1(2): 241-250. DOI: 10.1586/17512433.1.2.241.
Cangemi G, Barco S, Verrina EE, Scurati S, Melioli G and Alberighi ODC (2013). Micromethod for quantification of cinacalcet in human plasma by liquid chromatography–tandem mass spectrometry using a stable isotope-labeled internal standard.Ther Drug Monit 35(1): 112–117.
Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, and Martin D (2005). Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathy-roidism. Kidney int 67(2): 467-476. DOI: 10.1111/j. 1523-1755.2005.67103.x.
Cunningham AR, Rosenkranz HS, Zhang YP, and Klopman G (1998). Identification of genotoxic and non-genotoxic alerts for cancer in mice: the carcinogenic potency database. Mutat Res 398(1): 1-17. DOI: 10.1016/S0027-5107(97)00202-9.
Darwish I, AlShehri M, Sultan M, Shalaby H and Alzoman H (2013). Determination of cinacalcet hydrochloride by capillary electrophoresis with photodiode array detection. Instrum Sci Technol 42(1): 27-37. DOI: 10.1080/10739149.2013.832292.
Darwish IA, Al-Shehri MM and El-Gendy MA (2012). Novel spectrophotometric method for determination of cinacalcet hydrochloride in its tablets via derivatization with 1,2-naphthoquinone-4-sulphonate. Chem Cent J 6(1): 1-8. DOI: 10.1186/1752-153x-6-11.
Darwish IA, Al-Sheri MM and Al-Gendy MA (2013). A highly sensitive fluorimetric method for determination of cinacalcet hydrochloride in tablets and plasma via derivatization with 7-chloro-4-nitrobenzoxadiazole.Curr Anal Chem 9(3): 504-512. DOI:10.2174/1573411011309030020.
El-Haj BM, Al-Amri AM, Hassan MH, Bin-Khadem RK and Al-Hadi AA (2000). A GC-MS method for the detection of toluene and ethylbenzene in volatile substance abuse. J Anal Toxicol 24(6): 390-394. DOI: 10.1093/jat/24.6.390.
Franceschini N, Joy MS and Kshirsagar A (2003).Cinacalcet HCl: A calcimimeticagent for the management of primary and secondary hyperparathyroidism. Expert OpinInvestig Drugs 12(8): 1413-1421. DOI:10.1517/13543784.12.8.1413.
Hiatt HH, Watson JD and Winsten JA (1977). Origins of human cancer / mechanisms of carcinogenesis, Book B. Cold Spring Harbor Laboratory, New York.
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (2018). Analytical Procedure Development and Revision of Q2(R1) Analytical Validation Q14, Harmonized Tripati Guideline: Final Concept Paper, Geneva, Switzerland.
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use(2017). Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7 (R1), ICH Steering Committee: Concept Paper, Geneva, Switzerland.
Jacobson-Kram D, and McGovern T (2007). Toxicological overview of impurities in pharmaceutical products. Adv Drug Deliv Rev 59(1): 38-42. DOI: 10.1016/j.addr.2006.10.007.
Kumar GN, Sproul G, Poppe L, Turner S, Gohdes M, Ghoborah H, Padhi D and Roskos L (2004). Metabolism and disposition of calcimimeticagent cinacalcet HCl in humans and animal models. Drug Metab Dispos 32(12): 1491-1500. DOI: 10.1124/dmd. 104.000604.
Lava R, Aimo E, Menegus L, Pojana G and Marcomini A (2013). Determination of benzotrifluoride derivative compounds in groundwater. Anal Chim Acta 804: 126-134. DOI: 10.1016/ j.aca.2013.10.006.
Leblanc B, Charuel C, Ku W, and Ogilvie R (2004). Acceptability of low levels of genotoxic impurities in new drug substances.Int J Pharm Med 18(4): 215-220. DOI: 10.2165/00124363-200418040-00003.
Loni AB, Ghante MR and Sawant SD (2012). Spectrophotometric estimation of cinacalcet hydrochloride in bulk and tablet dosage form. Int J Pharm Phar Sci 4(3): 513-515.
Miller EC, and Miller JA (1981). Searches for ultimate chemical carcinogens and their reactions with cellular macro molecules.Cancer 47(10): 2327-2345. DOI:10.1002/1097-0142 (19810515)47:10<2327::aid-cncr2820471003>3.0.co;2-z.
Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, VanWagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D and Martin D (2003). Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308(2): 627-635. DOI: 10.1124/jpet.103.057273.
Pereira L, Meng C, Marques D and Frazao JM (2018). Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. Clin Kidney J 11(1): 80-88. DOI: 10.1093/ckj/sfx125.
Ravinder V, Ashok S, Varma MS, Babu CVR, Shanker K and Balaswamy G (2009). A validated chiral LC method for the enantiomeric separation of cinacalcet hydrochloride. Chromato-graphia 70(1): 229-232. DOI:10.1365/s10337-009-1129-5.
Reddy PS, Raju TVR, Raju PS, Varma NS and Babu KS (2015). Development and validation of a stability-indicating RP-UPLC method for the estimation of impurities in cinacalcet hydrochloride API and its formulation. Sci Pharm 83: 583-595. DOI: 10.3797/scipharm.1502-06.
Reddy SR, Reddy KH, Kumar MN, Reddy PM, Reddy JVR and Sharma HK (2018). A validated GC-MS method for the determination of 3-(trifluoromethyl) cinnamaldehyde content in cinacalcet hydrochloride drug substance. Eur J Biomed Pharm Sci 5(3): 490-496.
Sigala A, Babu CHVR, Varma MS and Balaswamy G (2009). A new validated liquid chromatographic method for the determination of impurities in cinacalcet hydrochloride. Anal Chem Indian J 8(4): 594-599.
USP (2014). Unites States Pharmacopeia-national formulary [USP 37 NF 32]. Rockville, Md United States Pharmacopeial Conv.
Wang EH, Combe PC and Schug KA (2016). Multiple reaction monitoring for direct quantitation of intact proteins using a triple quadrupole mass spectrometer. J Am Soc Mass Spectrom 27(5): 886-896. DOI: 10.1007/s13361-016-1368-2.
Wani TA, Khalil NS, Darwish I, Iqbal M and Bakheit AH (2014). Highly sensitive and simple validated ultra-performance liquid chromatography/ tandem mass spectrometry method for the determination of cinacalcet in human plasma. Curr Pharm Anal 10(1): 51-57. DOI: 10.2174/1573412909999131125151512.
Yang F, Wang H, Zhao Q, Liu H, Hu P and Jiang J (2012). Determination of cinacalcet hydrochloride in human plasma by liquid chromatography–tandem mass spectrometry. J Pharm Biomed Anal 61:237-241. DOI: 10.1016/j.jpba.2011.10.022.
